CA2233445A1 - Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies - Google Patents

Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies Download PDF

Info

Publication number
CA2233445A1
CA2233445A1 CA002233445A CA2233445A CA2233445A1 CA 2233445 A1 CA2233445 A1 CA 2233445A1 CA 002233445 A CA002233445 A CA 002233445A CA 2233445 A CA2233445 A CA 2233445A CA 2233445 A1 CA2233445 A1 CA 2233445A1
Authority
CA
Canada
Prior art keywords
mea
administration
cells
patient
transfer factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002233445A
Other languages
English (en)
Inventor
Samir Chachoua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2233445A1 publication Critical patent/CA2233445A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouvelles compositions et applications de 2-mercaptoéthanolamine (2-MEA) et d'aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (II). Ces compositions sont utilisées seules ou en association avec d'autres facteurs, agents ou procédés physiques, chimiques et/ou biologiques. Il peut s'agir de précurseurs, d'intermédiaires, de produits finis, de catalyseurs, de promoteurs et/ou d'autres facteurs, agents ou procédés mis en jeu directement ou indirectement depuis l'application initiale de la composition jusqu'à l'obtention du résultat recherché.
CA002233445A 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies Abandoned CA2233445A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US60/004,281 1995-09-25

Publications (1)

Publication Number Publication Date
CA2233445A1 true CA2233445A1 (fr) 1997-04-03

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002233445A Abandoned CA2233445A1 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
CA002233015A Abandoned CA2233015A1 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002233015A Abandoned CA2233015A1 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Country Status (5)

Country Link
EP (2) EP0858327A2 (fr)
JP (1) JPH11514990A (fr)
AU (2) AU6999096A (fr)
CA (2) CA2233445A1 (fr)
WO (2) WO1997011667A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US7939109B1 (en) * 1999-10-04 2011-05-10 John Carter Method of treating neoplastic disease in a human or animal patient
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
KR20030077743A (ko) * 2002-03-26 2003-10-04 변현규 In½
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
EP2278984A4 (fr) 2007-11-30 2013-02-27 Ramaekers Family Trust Compositions et procédés d'amélioration de la fertilité
WO2010093606A1 (fr) * 2009-02-11 2010-08-19 Martin Heath Bluth Echange réciproque sérum/plasma pour le traitement du cancer
US11110303B2 (en) 2014-11-26 2021-09-07 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
WO1994028934A1 (fr) * 1993-06-07 1994-12-22 Center For Special Immunology Traitement adoptif de reconstitution immunitaire pour des patients atteints d'immunodeficiences acquises

Also Published As

Publication number Publication date
EP0853486A2 (fr) 1998-07-22
AU6999096A (en) 1997-04-17
EP0858327A2 (fr) 1998-08-19
WO1997011667A2 (fr) 1997-04-03
WO1997011667A3 (fr) 1997-06-12
EP0853486A4 (fr) 2001-09-26
WO1997011666A3 (fr) 1997-06-19
JPH11514990A (ja) 1999-12-21
AU7143196A (en) 1997-04-17
CA2233015A1 (fr) 1997-04-03
WO1997011666A2 (fr) 1997-04-03

Similar Documents

Publication Publication Date Title
CA2233445A1 (fr) Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
EP2286832B1 (fr) Compositions bactériennes pour le traitement du cancer
US20200384040A1 (en) Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor
Renoux et al. Potentiation of T-cell mediated immunity by levamisole.
EP0726772B1 (fr) Procede de sensibilisation de cellules cancereuses destinees a la lyse induite par cellules &#34;tueuses&#34;
Fang et al. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei
Xie et al. Research progress in inducing immunogenic cell death of tumor cells
US6258847B1 (en) Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
Farber Clinical and biological studies with actinomycins
WO2017222295A1 (fr) Composition pour la prévention et le traitement du virus de la grippe, comprenant des bactéries lactiques dérivées du kimchi et de la pâte de soja comme ingrédient actif
UA79952C2 (en) MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
Malkov et al. Antitumor features of Bacillus oligonitrophilus KU-1 strain
AU7214700A (en) Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper (II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
Erciyas Murrembeena (AU)
JPS6212721A (ja) 椎茸霊芝の製造法
Nowotny et al. Studies on host defenses enhanced by endotoxins: a brief review
JP2001231495A (ja) 好酸球集積抑制作用を有する食品
RU2587332C1 (ru) Способ лечения больных деструктивными формами туберкулеза легких
RU2207127C1 (ru) Способ лечения экспериментального туберкулеза
OKURA et al. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice
Miura et al. Effects of levamisole administration on treatment with 6-mercaptopurine riboside of mice bearing L1210 leukemia cells
Hoffmann et al. Antiproliferative effect of retinoids and interferon α in combination with irradiation on human tumor cell lines
Adler et al. Effect of liposomal allogeneic melanoma vaccine with IL-2 on cellular immune responses
Goey et al. Adopive immunotherapy with interleukin-2 (IL2)+ interferon (αIFN)+ IL2-activated lymphocytes (LAK) in metastatic renal cell cancer
Becker et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead